# A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)

> **NCT05526716** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1080 (actual)

## Conditions studied

- Pneumonia, Pneumococcal

## Interventions

- **BIOLOGICAL:** V116
- **BIOLOGICAL:** QIV
- **BIOLOGICAL:** Matching Placebo for V116

## Key facts

- **NCT ID:** NCT05526716
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-23
- **Primary completion:** 2023-06-21
- **Final completion:** 2023-06-21
- **Target enrollment:** 1080 (ACTUAL)
- **Last updated:** 2025-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05526716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05526716, "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05526716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*